all the information, none of the junk | biotech • healthcare • life sciences

The 20-Year Outlook for San Diego Life Sciences: Sold Out? Not Anymore

Xconomy San Diego — 

You spoke, and we listened.

Demand has been surging for the event we’re organizing on the 20-year outlook for San Diego’s life sciences cluster. We sold out all 130 tickets with three weeks left before the big event on March 31. While I must say we were pretty darn happy about that, it also meant many would-be attendees would be left out. But thanks to the gracious and flexible hosts over at Biogen Idec, we found a solution: We’re moving this event into a bigger commons on their campus, with enough room for 30 more regular seats, and 10 front-row VIP tickets.

In case you missed it, this event will feature an interactive panel discussion with Paul Schimmel of The Scripps Research Institute, Dan Bradbury of Amylin Pharmaceuticals, and Fred “Rusty” Gage of the Salk Institute. John Mendlein, the chairman of Fate Therapeutics, will moderate. This stellar panel will be followed by quick 3-minute “burst” presentations by a handful of organizations pursuing innovative biotech ideas in San Diego—Ambrx, Biogen Idec New Ventures, Helixis, Receptos, and VentiRx Pharmaceuticals.

I am flying in from Seattle for this, and Xconomy’s founder and editor in chief Bob Buderi will also be on hand from Boston. My job will be to roam with the microphone to help people aim their questions at this great lineup of speakers. When that is done, Bob and I will stick around the networking reception so we can get to know some of our readers a little better. See you on the 31st.